Cancer risk in relation to serum copper levels
- PMID: 2743325
Cancer risk in relation to serum copper levels
Abstract
A nested, matched case-control study was conducted to assess the relationship between serum levels of copper and the subsequent risk of cancer. One hundred thirty-three cases of cancer were identified during 1974-1984 among 5000 members of a northwest Washington State employee cohort from whom serum specimens had been previously obtained and stored. Two hundred forty-one controls were selected at random from the cohort and were matched to the cases on the basis of age, sex, race, and date of blood draw. Serum copper levels were measured by atomic absorption spectrometry. Risk of a subsequent diagnosis of cancer was positively associated with serum copper levels, but only among those cases diagnosed within 4 years of the time the serum specimens were collected. Among cases diagnosed more than 4 years after specimen collection, there was no consistent association between serum copper levels and risk. Adjustment for age, sex, race, occupational status, cigarette smoking, family history of cancer, alcohol consumption, and, among females, use of exogenous hormones had no appreciable effect on these relationships. The findings suggest that the presence of cancer may increase serum copper levels several years prior to its diagnosis. They are less supportive of the hypothesis that serum copper levels affect cancer risk.
Similar articles
-
Serum insulin-like growth factor (IGF) and IGF-binding protein levels and risk of lung cancer: a case-control study nested in the beta-Carotene and Retinol Efficacy Trial Cohort.Cancer Epidemiol Biomarkers Prev. 2002 Nov;11(11):1413-8. Cancer Epidemiol Biomarkers Prev. 2002. PMID: 12433720 Clinical Trial.
-
Serum transforming growth factor-beta1 levels and pancreatic cancer risk: a nested case-control study (Japan).Cancer Causes Control. 2006 Oct;17(8):1077-82. doi: 10.1007/s10552-006-0048-0. Cancer Causes Control. 2006. PMID: 16933058
-
Relation of prediagnostic serum estrogen and androgen levels to breast cancer risk.Cancer Epidemiol Biomarkers Prev. 1996 Jul;5(7):533-9. Cancer Epidemiol Biomarkers Prev. 1996. PMID: 8827358
-
Serum retinol and risk of subsequent cancer: extension of the Evans County, Georgia, study.J Natl Cancer Inst. 1984 Dec;73(6):1455-8. J Natl Cancer Inst. 1984. PMID: 6595454
-
Serum levels of selenium and retinol and the subsequent risk of cancer.Am J Epidemiol. 1988 Sep;128(3):515-23. doi: 10.1093/oxfordjournals.aje.a114999. Am J Epidemiol. 1988. PMID: 3046338 Review.
Cited by
-
Quantitative analysis of serum levels of trace elements in patients with oral submucous fibrosis and oral squamous cell carcinoma: A randomized cross-sectional study.J Oral Maxillofac Pathol. 2014 Jan;18(1):46-51. doi: 10.4103/0973-029X.131902. J Oral Maxillofac Pathol. 2014. PMID: 24959037 Free PMC article.
-
Current Biomedical Use of Copper Chelation Therapy.Int J Mol Sci. 2020 Feb 6;21(3):1069. doi: 10.3390/ijms21031069. Int J Mol Sci. 2020. PMID: 32041110 Free PMC article. Review.
-
Distinct mechanisms of site-specific oxidative DNA damage by doxorubicin in the presence of copper(II) and NADPH-cytochrome P450 reductase.Cancer Sci. 2003 Aug;94(8):686-91. doi: 10.1111/j.1349-7006.2003.tb01503.x. Cancer Sci. 2003. PMID: 12901793 Free PMC article.
-
Phase 2 trial of copper depletion and penicillamine as antiangiogenesis therapy of glioblastoma.Neuro Oncol. 2005 Jul;7(3):246-53. doi: 10.1215/S1152851704000869. Neuro Oncol. 2005. PMID: 16053699 Free PMC article. Clinical Trial.
-
Phytoagents for cancer management: regulation of nucleic acid oxidation, ROS, and related mechanisms.Oxid Med Cell Longev. 2013;2013:925804. doi: 10.1155/2013/925804. Epub 2013 Dec 25. Oxid Med Cell Longev. 2013. PMID: 24454991 Free PMC article. Review.